Topical Calcineurin Inhibitors in the Treatment of Atopic Dermatitis
Tóm tắt
Purpose: To summarize success rates of the topical calcineurin inhibitors tacrolimus and pimecrolimus in treating atopic dermatitis.
Methods: Randomized controlled trials (RCTs) comparing either drug to themselves (i.e. dose-ranging studies), each other, the vehicle (or placebo), or corticosteroids were obtained from Medline, EMBASE, and Cochrane databases. Two reviewers identified studies and extracted data, a third reviewer adjudicated disagreements. Outcomes included success, as defined by 90%, 75%, or 50% reductions from baseline in Eczema Area and Severity Index (EASI) scores or equivalent at 1, 3, 6, and 12 months, and also the difference between drug and vehicle (placebo). Rates were combined using a random effects meta-analytic model.
Results: Of 180 articles identified, 165 were rejected (142 not RCTs/inappropriate outcome, 23 inappropriate/unextractable data). We included 15 articles reporting on 16 trials (nine tacrolimus and seven pimecrolimus trials) involving a total of 5301 patients, of whom 2107 received tacrolimus, 1225 received pimecrolimus and 1969 patients were controls. Tacrolimus reduced EASI scores by 65.6% at 1 month and 73.0% at 3 months; pimecrolimus reduced scores by 61.5% at 1 month, 60.3% at 6 months, and 61.9% at 12 months. When the difference in EASI score reductions were compared between active drug and placebo, tacrolimus success was 51.5% above placebo at 1 month and pimecrolimus was 45.9% higher at 1 month, 24.9% at 6 months, and 16.1% at 12 months.
Conclusions: Success rates for tacrolimus and pimecrolimus were statistically similar. However, tacrolimus rates were consistently higher numerically than those for pimecrolimus, and tacrolimus was used in patients with more severe disease. A head-to-head RCT is required to determine if true differences exist between these drugs.
Tài liệu tham khảo
Leung DY, Bieber T. Atopic dermatitis. Lancet 2003; 361: 151–60
Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4: 1–191
Beltrani VS. The clinical spectrum of atopic dermatitis. J Allergy Clin Immunol 1999; 104: S87–98
Gianni LM, Sulli MM. Topical tacrolimus in the treatment of atopic dermatitis. Ann Pharmacother 2001; 35: 943–6
Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002; 110: 277–84
Leung DY. Pathogenesis of atopic dermatitis. J Allergy Clin Immunol 1999; 104: S99-S108
Leung D, Tharp M, Boguniewicz M. Atopic dermatitis. In: Freedberg I, editor. Fitzpatrick’s dermatology in general medicine. 5th ed. New York: McGraw Hill, 1999: 1464–80
Wollenberg A, Sharma S, von Bubnoff D, et al. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2001; 107: 519–25
Cheer SM, Plosker GL. Tacrolimus ointment: a review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol 2001; 2: 389–406
Reitamo S, Remitz A, Kyllonen H, et al. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol 2002; 3: 381–8
Hebert A, Warken K, Cherill R. Pimecrolimus cream 1%: a new development in nonsteroid topical treatment of inflammatory skin diseases. Semin Cutan Med Surg 2001; 20: 260–7
Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 539–46
Gupta A, Adamiak A, Chow M. Tacrolimus: a review of its use for the management for dermatoses. J Eur Acad Dermatol Venereol 2002; 16: 100–14
Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs 2002; 62: 817–40
Fleischer Jr A. Atopic dermatitis: an update for the next millennium. J Allergy Clin Immunol 1999; 104: S126–30
Boguniewicz M. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children: Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102: 637–44
Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 547–55
Soter NA, Fleischer Jr AB, Webster G, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 2001; 44: S39–46
Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44: S47–57
Meurer M, Folster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205: 271–7
Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495–504
Wahn U, Bos J, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: 1–8
Van Leent E, Graber M, Thurston M, et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134: 805–9
Luger T, Van Leent E, Graeber M, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001; 144: 788–94
Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis: European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 337: 816–21
Einarson TR, Leeder J, Koren G. A method for meta-analysis of epidemiological studies. Drug Intell Clin Pharm 1988; 22: 813–23
Einarson TR, McGhan W, Bootman J, et al. Meta-analysis: quantitative integration of independent research results. Am J Hosp Pharm 1985; 42: 1957–64
Hanifin J, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980; 92: 44–7
Williams H, Burney P, Pembroke A, et al. The UK Working Party’s diagnostic criteria for atopic dermatitis: III. Independent hospital validation. Br J Dermatol 1994; 131: 406–16
Seymour J, Keswick B, Hanifin J, et al. Clinical effects of diaper types on the skin of normal infants and infants with atopic dermatitis. J Am Acad Dermatol 1987; 17: 988–97
Jadad A, Moore R, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1–12
Cochran W. The combination of estimates from different experiments. Biometrics 1954; 10: 101–29
Einarson TR. Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example. Clin Ther 1997; 19: 559–69
Reitamo S, for the European Tacrolimus Ointment Study Group. A 6 month, multicentre, double-blind, comparative study to evaluate the efficacy and safety of tacrolimus (FK506) ointment regimen compared to hydrocortisone ointment regimen in adults with moderate to severe atopic dermatitis. J Eur Acad Dermatol Venerol 2003; 17 Suppl. 1: 52–3
Granlund H, Remitz A, Kyllonen H, et al. Treatment of lichenified atopic eczema with tacrolimus ointment. Acta Derm Venereol 2001; 81: 314–5
Hanifin J, Ling M, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001; 44: S28–38
Ho V, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142: 155–62
Rico MJ, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis: clinical and pharmacologic effects. Allergy Asthma Proc 2002; 23: 191–7
Meingassner JG, Kowalsky E, Schwendinger H, et al. Pimecrolimus does not affect Langerhans cells in murine epidermis. Br J Dermatol 2003; 149: 853–7
Chapman MS, Schachner L, Breneman D, et al. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric and adult patients [poster 11]. Annual meeting of the Society of Pediatrics Dermatology; 2003 Jun 18–21; Seattle